A key educational message from ASH 2017

FAQ Library published on January 12, 2018
Download Transcript Download Audio
Sagar Lonial, MD, FACP
Chair and Professor
Department of Hematology and Medical Oncology
Chief Medical Officer
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia

Welcome to Managing Myeloma. I am Dr. Sagar Lonial. What we are going to talk about in this installment is that the treatment landscape for multiple myeloma continues to expand with many new drugs and combinations. One of the important educational messages that comes out at ASH is the idea that early relapse is the new newly diagnosed myeloma. What I mean by that is our concepts have been to treat very aggressively early on, to try and maximize depth of response. What we have seen from phase 3 updates at this meeting is that patients who have good depth of response with MRD negativity or overall high response rates in CR rate in the early salvage setting actually have prolonged progression-free and overall survival. What this means is the idea of using sequential single agents as salvage is probably gone in myeloma. Triplets are the ruling approach for the day, even in early relapse, and this approach can result in longer PFS and overall survival. Thank you very much for viewing this activity.

View Accredited Highlights in Multiple Myeloma from ASH 2017 here.

Last modified: January 11, 2018
Related Items by Author
Practice-changing trials to watch for in 2018
Sagar Lonial, MD, FACP
FAQ Library published on January 24, 2018
Is there a role for Bcl-2 directed treatment for patients with translocation 11;14?
Sagar Lonial, MD, FACP
FAQ Library published on October 11, 2017
How will the new IMWG definition of active multiple myeloma impact clinical practice?
Sagar Lonial, MD, FACP
FAQ Library published on August 18, 2016
How do we determine which patients will benefit the most from treatment with daratumumab and elotuzumab?
Sagar Lonial, MD, FACP
FAQ Library published on July 18, 2016
What is the role of SPEP, UPEP and immunofixation in managing multiple myeloma patients?
Sagar Lonial, MD, FACP
FAQ Library published on July 6, 2016
Is BD or KD a standard of care in relapsed/refractory multiple myeloma?
Sagar Lonial, MD, FACP
FAQ Library published on June 15, 2016
Which is the best indicator of improved outcomes in multiple myeloma: sCR, CR, IFCR or MCR?
Sagar Lonial, MD, FACP
FAQ Library published on May 10, 2016
What new classes of therapy are emerging for multiple myeloma?
Sagar Lonial, MD, FACP
FAQ Library published on March 10, 2016
How does one define high-risk smoldering or asymptomatic multiple myeloma?
Sagar Lonial, MD, FACP
FAQ Library published on November 6, 2014
What are the mechanisms of renal complications in patients with multiple myeloma?
Sagar Lonial, MD, FACP
FAQ Library published on March 15, 2011 in Comorbidities/SEs